Search
for
Sort by
Research 31–60 of 54
- BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer
- Tumor Angiogenesis and Anti-angiogenic Therapy
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- Assessing the cost-effectiveness of DNA origami nanostructures for targeted delivery of anti-cancer drugs to tumours
- Bubble-Based Drug Delivery Systems: Next-Generation Diagnosis to Therapy
- Merkel cell carcinoma: updates in tumor biology, emerging therapies, and preclinical models
- Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib
- Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
- Combined drug triads for synergic neuroprotection in retinal degeneration
- Cancer-Related Alopecia: From Etiologies to Global Management
- Unusual progression of renal cell carcinoma with carcinomatosis peritoneii and Krukenberg tumour and alopecia with sunitinib therapy in young female
- Recent Insights in Multi‐Target Drugs in Pharmacology and Medicinal Chemistry
- Therapies and nanotherapies for cervical cancer (Review)
- Lymphatic vessel: origin, heterogeneity, biological functions, and therapeutic targets
- 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies
- Drug-induced hair pigmentation: Clinical perspectives and updates
- Premature Graying of Hair: A Comprehensive Review and Recent Insights
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Circulating MicroRNA Signatures in Severe Alopecia Areata: Diagnostic Discrimination, Pathway Analysis, and Therapeutic Implications
- Spotlight commentary: Navigating the cutaneous side effects of chemotherapy
- Unique Circulating MicroRNA Signatures Distinguish Severe Alopecia Areata from Other Inflammatory Skin Diseases
- The possibilities of correction of premature greying of hair and involutive hair changes
- Management of Older Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario
- Rapid hair depigmentation in patient treated with pazopanib
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Targeting the Hippo/YAP/TAZ signalling pathway: Novel opportunities for therapeutic interventions into skin cancers
- Use of natural molecules as anti-angiogenic inhibitors for vascular endothelial growth factor receptor
- S1‐Guideline Cutaneous Angiosarcomas – Update 2021
- Synthetic Approaches for Pharmacologically Active Decorated Six-Membered Diazines